Liezl Gambe

Peninsula Energy (ASX:PEN) reported operational developments at its Lance Uranium Project in Wyoming.

Dateline Resources (ASX:DTR) saw its shares rally after the US Department of Justice filed a motion to lift an operational injunction at the Colosseum Project.

Mayne Pharma (ASX:MYX) agreed to pay US$0.7 million to settle a civil complaint filed by attorneys general from 49 US states and territories.

Northern Star Resources (ASX:NST) has unanimously rejected an unsolicited takeover proposal from Gold Fields.

The S&P/ASX 200 Index is poised for a flat opening as investors prepare for an expected fourth interest rate increase this year.

Firefly Neuroscience (NASDAQ:AIFF) and NeuroSigma announced a partnership to introduce NeuroSigma’s Monarch eTNS System to clinicians using Firefly’s Evoke brain-function assessment platform.

Fate Therapeutics (NASDAQ:FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support the Phase 2 RECLAIM-LN clinical trial evaluating FT819, an off-the-shelf CAR T-cell therapy.

Addex Therapeutics (NASDAQ:ADXN) announced it regained full global rights to its GABAB positive allosteric modulator assets from Indivior UK, including a development candidate previously selected under their research collaboration.

Johnson Outdoors (NASDAQ:JOUT) announced that its board of directors approved a quarterly cash dividend of $0.33 per Class A share and $0.30 per Class B share, payable on October 23, 2026.

REGENXBIO (NASDAQ:RGNX) announced three-year Phase II results from the ALTITUDE clinical trial evaluating investigational sura-vec for non-proliferative diabetic retinopathy (NPDR).